Semnur Pharmaceuticals, Inc. (SMNR)

Semnur Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	163.18	157.87	2.98	1.64	1.65
Research & Development	4.37	2.55	1.71	1.62	2.12
Operating Expenses	167.55	160.42	4.69	3.26	3.77
Operating Income	-167.55	-160.42	-4.69	-3.26	-3.77
Pretax Income	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income to Common	-167.68	-160.42	-4.69	-3.26	-3.77
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	220	205	200	160	160
Shares Outstanding (Diluted)	220	205	200	160	160
Shares Change	-0.05%	2.39%	25.00%	-	-
EPS (Basic)	-0.76	-0.78	-0.02	-0.02	-0.02
EPS (Diluted)	-0.76	-0.78	-0.02	-0.02	-0.02
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
EBIT	-167.55	-160.42	-4.69	-3.26	-3.77

Data Source: S&P Global Market Intelligence Last updated: Aug 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 19, 2026

Data Sources Report a data error